Advertisement

Hyperuricemia in Tendons

  • Isabel AndiaEmail author
  • Michele Abate
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 920)

Abstract

Hyperuricemia, particularly gout, and the immune inflammatory response are highly integrated. Both, long standing hyperuricemia and monosodium urate (MSU) crystal deposition can challenge tendon homeostasis because of their potential to cause inflammation to the host. Knowledge is emerging from clinical imaging research depicting where MSU crystals deposit, including patellar tendon, triceps and quadriceps tendons. Remarkably, subclinical tendon inflammation and damage are also present in asymptomatic hyperuricemia. Monosodium urate crystals act as danger activating molecular patterns (DAMPs), activating the inflammasome and inducing the secretion of IL-1beta, a key mediator of the inflammatory response. The crucial role of IL-1beta in driving the inflammatory events during gout attacks is supported by the clinical efficacy of IL-1beta blockade. Some data implicating IL-1beta as an initiator of tendinopathy exist, but the link between hyperuricemia and the development of tendinopathy remains to be validated. Further knowledge about the interactions of uric acid with both innate immune and tendon cells, and their consequences may help to determine if there is a subclass of hyperuricemic-tendinopathy.

Keywords

Uric Acid Patellar Tendon Crystal Deposition Serum Urate Quadriceps Tendon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ADAMTS1

A Disintegrin-Like And Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 1

ADAMTS4

A Disintegrin-Like And Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 4

ADAMTS5

A Disintegrin-Like And Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 5

CRP

C reactive protein

DAMP

Danger Associated Molecular patterns

DECT

dual energy computerized tomography

DNA

deoxynucleic acid

IL-1beta, IL-1alpha, IL-6, IL-8, IL-18

Interleukins

MCP-1/CCL2

macrophage chemotactic protein

MMP-2, MMP-3, MMP-13

metalloproteinases

MSU

monosodium urate

NLRP3

NOD-like receptor protein 3

NSAIDs

non-steroidal anti-inflammatory drugs

PGE2

prostaglandin E2

RNA

ribonucleic acid

TLR2, TLR4

Toll like receptors

TNF-alpha

tumor necrosis factor alpha

VEGF

vascular endothelial growth factor

References

  1. 1.
    Abate M, Schiavone C, Salini V, Andia I (2013) Occurrence of tendon pathologies in metabolic disorders. Rheumatology (Oxford) 52(4):599–608CrossRefGoogle Scholar
  2. 2.
    Ackermann PW, Domeij-Arverud E, Leclerc P, Amoudrouz P, Nader GA (2013) Anti-inflammatory cytokine profile in early human tendon repair. Knee Surg Sports Traumatol Arthrosc 21(8):1801–1806CrossRefPubMedGoogle Scholar
  3. 3.
    Alfredson H (2005) The chronic painful Achilles and patellar tendon: research on basic biology and treatment. Scand J Med Sci Sports 15(4):252–259CrossRefPubMedGoogle Scholar
  4. 4.
    Andia I, Sanchez M, Maffulli N (2010) Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther 10(10):1415–1426CrossRefPubMedGoogle Scholar
  5. 5.
    Andia I, Rubio-Azpeitia E, Maffulli N (2014) Hyperuricemic PRP in tendon cells. Biomed Res Int 2014:926481CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Andia I, Rubio-Azpeitia E (2014) Angiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia. Muscles Ligaments Tendons J 4(3):292–297PubMedPubMedCentralGoogle Scholar
  7. 7.
    Andia I, Rubio-Azpeitia E, Maffulli N (2015) Platelet-rich plasma modulates the secretion of inflammatory/angiogenic proteins by inflamed tenocytes. Clin Orthop Relat Res 473(5):1624–1634CrossRefPubMedGoogle Scholar
  8. 8.
    Aslam N, Lo S, McNab I (2004) Gouty flexor tenosynovitis mimicking infection: a case report emphasising the value of ultrasound in diagnosis. Acta Orthop Belg 70(4):368–370PubMedGoogle Scholar
  9. 9.
    Bond JR, Sim FH, Sundaram M (2004) Radiologic case study. Gouty tophus involving the distal quadriceps tendon. Orthopedics 27(1):18, 90–92Google Scholar
  10. 10.
    Bullocks JM, Downey CR, Gibler DP, Netscher DT (2009) Crystal deposition disease masquerading as proliferative tenosynovitis and its associated sequelae. Ann Plast Surg 62(2):128–133CrossRefPubMedGoogle Scholar
  11. 11.
    Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 82(3):421–426CrossRefPubMedGoogle Scholar
  12. 12.
    Chen CK, Chung CB, Yeh L, Pan HB, Yang CF, Lai PH, Liang HL, Resnick D (2000) Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. AJR Am J Roentgenol 175(3):655–659CrossRefPubMedGoogle Scholar
  13. 13.
    Chhana A, Callon KE, Pool B, Naot D, Watson M, Gamble GD, McQueen FM, Cornish J, Dalbeth N (2011) Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis 70(9):1684–1691CrossRefPubMedGoogle Scholar
  14. 14.
    Chhana A, Callon KE, Dray M, Pool B, Naot D, Gamble GD, Coleman B, McCarthy G, McQueen FM, Cornish J, Dalbeth N (2014) Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout. Ann Rheum Dis 73(9):1737–1741CrossRefPubMedGoogle Scholar
  15. 15.
    Dalbeth N, Kalluru R, Aati O, Horne A, Doyle AJ, McQueen FM (2013) Tendon involvement in the feet of patients with gout: a dual-energy CT study. Ann Rheum Dis 72(9):1545–1548CrossRefPubMedGoogle Scholar
  16. 16.
    de Mos M, Joosten LA, Oppers-Walgreen B, van Schie JT, Jahr H, van Osch GJ, Verhaar JA (2009) Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes. J Orthop Res 27(8):1043–1047CrossRefPubMedGoogle Scholar
  17. 17.
    Fredberg U, Stengaard-Pedersen K (2008) Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. Scand J Med Sci Sports 18(1):3–15CrossRefPubMedGoogle Scholar
  18. 18.
    Fedorczyk JM, Barr AE, Rani S, Gao HG, Amin M, Amin S, Litvin J, Barbe MF (2010) Exposure-dependent increases in IL-1beta, substance P, CTGF, and tendinosis in flexor digitorum tendons with upper extremity repetitive strain injury. J Orthop Res 28(3):298–307PubMedPubMedCentralGoogle Scholar
  19. 19.
    Forbess LJ, Fields TR (2012) The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. Semin Arthritis Rheum 42(2):146–154CrossRefPubMedGoogle Scholar
  20. 20.
    Gililland JM, Webber NP, Jones KB, Randall RL, Aoki SK (2011) Intratendinous tophaceous gout imitating patellar tendonitis in an athletic man. Orthopedics 34(3):223CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Grainger R, McLaughlin RJ, Harrison AA, Harper JL (2013) Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout. Rheumatology (Oxford) 52(6):1018–1021CrossRefGoogle Scholar
  22. 22.
    Gunawardena H, Churn P, Blake DR (2005) Running for gout research. Rheumatology (Oxford) 44(8):1073–1074CrossRefGoogle Scholar
  23. 23.
    Kanevets U, Sharma K, Dresser K (2009) Shi Y A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol 182(4):1912–1918CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kimura-Hayama E, Criales-Vera S, Nicolaou S, Betanzos JL, Rivera Y, Alberú J, Rull-Gabayet M, Hernández-Molina G (2014) A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. J Clin Rheumatol 20(6):306–309PubMedGoogle Scholar
  25. 25.
    Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE (2012) Nature versus nurture in gout: a twin study. Am J Med 125(5):499–504CrossRefPubMedGoogle Scholar
  26. 26.
    Kuo YL, Hsu CC, Kuo LC, Wu PT, Shao CJ, Wu KC, Wu TT, Jou IM (2015) Inflammation is present in de quervain disease–correlation study between biochemical and histopathological evaluation. Ann Plast Surg 74(Suppl 2):S146–S151CrossRefPubMedGoogle Scholar
  27. 27.
    Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324(1):1–7CrossRefPubMedGoogle Scholar
  28. 28.
    Lagoutaris ED, Adams HB, DiDomenico LA, Rothenberg RJ (2005) Longitudinal tears of both peroneal tendons associated with tophaceous gouty infiltration. A case report. J Foot Ankle Surg 44(3):222–224, Muscles Ligaments Tendons J. 2014 Nov 17;4(3):292–297CrossRefPubMedGoogle Scholar
  29. 29.
    Legerlotz K, Jones ER, Screen HR, Riley GP (2012) Increased expression of IL-6 family members in tendon pathology. Rheumatology (Oxford) 51(7):1161–1165CrossRefGoogle Scholar
  30. 30.
    Lian Ø, Scott A, Engebretsen L, Bahr R, Duronio V, Khan K (2007) Excessive apoptosis in patellar tendinopathy in athletes. Am J Sports Med 35(4):605–611CrossRefPubMedGoogle Scholar
  31. 31.
    Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R (2005) TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 174(8):5016–5023CrossRefPubMedGoogle Scholar
  32. 32.
    Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R (2005) Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 52(9):2936–2946CrossRefPubMedGoogle Scholar
  33. 33.
    Martin WJ, Grainger R, Harrison A, Harper JL (2010) Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival. J Rheumatol 37(6):1228–1235CrossRefPubMedGoogle Scholar
  34. 34.
    Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241CrossRefPubMedGoogle Scholar
  35. 35.
    Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N (2015) Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis 75(4):652–659. pii: annrheumdis-2014-206191CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    McCarty DJ (1994) Gout without hyperuricemia. JAMA 271(4):302–303CrossRefPubMedGoogle Scholar
  37. 37.
    Melloni P, Valls R, Yuguero M, Sáez A (2004) An unusual case of tophaceous gout involving the anterior cruciate ligament. Arthroscopy 20(9):e117–e121CrossRefPubMedGoogle Scholar
  38. 38.
    Millar NL, Wei AQ, Molloy TJ, Bonar F, Murrell GA (2009) Cytokines and apoptosis in supraspinatus tendinopathy. J Bone Joint Surg (Br) 91(3):417–424CrossRefGoogle Scholar
  39. 39.
    Millar NL, Murrell GA, McInnes IB (2013) Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology (Oxford) 52(5):769–779CrossRefGoogle Scholar
  40. 40.
    Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, Wang J, King-Davis S, Evans RR (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52(7):1285–1292CrossRefGoogle Scholar
  41. 41.
    Naredo E, Uson J, Jiménez-Palop M, Martínez A, Vicente E, Brito E, Rodríguez A, Cornejo FJ, Castañeda S, Martínez MJ, Sanz J, Möller I, Batlle-Gualda E, Garrido J, Pascual E (2014) Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73(8):1522–1528CrossRefPubMedGoogle Scholar
  42. 42.
    Nirschl RP, Ashman ES (2003) Elbow tendinopathy: tennis elbow. Clin Sports Med 22(4):813–836CrossRefPubMedGoogle Scholar
  43. 43.
    Pearce CJ, Ismail M, Calder JD (2009) Is apoptosis the cause of noninsertional achilles tendinopathy? Am J Sports Med 37(12):2440–2444CrossRefPubMedGoogle Scholar
  44. 44.
    Perez-Ruiz F, Dalbeth N, Bardin T (2015) A review of uric acid, crystal deposition disease, and gout. Adv Ther 32(1):31–41CrossRefPubMedGoogle Scholar
  45. 45.
    Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henríquez P, Hernández-Díaz C, Vargas A, Hofmann F, Gutiérrez M (2011) Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther 13(1):R4CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Pingel J, Wienecke J, Kongsgaard M, Behzad H, Abraham T, Langberg H, Scott A (2013) Increased mast cell numbers in a calcaneal tendon overuse model. Scand J Med Sci Sports 23(6):e353–e360CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Puig JG, de Miguel E, Castillo MC, Rocha AL, Martínez MA, Torres RJ (2008) Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 27(6):592–595CrossRefPubMedGoogle Scholar
  48. 48.
    Radice F, Monckeberg JE, Carcuro G (2011) Longitudinal tears of peroneus longus and brevis tendons: a gouty infiltration. J Foot Ankle Surg 50(6):751–753CrossRefPubMedGoogle Scholar
  49. 49.
    Rock KL, Kataoka H, Lai JJ (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 9(1):13–23CrossRefPubMedGoogle Scholar
  50. 50.
    Rodas G, Pedret C, Català J, Soler R, Orozco L, Cusi M (2013) Intratendinous gouty tophus mimics patellar tendonitis in an athlete. J Clin Ultrasound 41(3):178–182CrossRefPubMedGoogle Scholar
  51. 51.
    Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, Lauretani F, Bandinelli S, Senin U, Ferrucci L (2006) Uric acid and inflammatory markers. Eur Heart J 27(10):1174–1181CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Scharpf RB, Mireles L, Yang Q, Köttgen A, Ruczinski I, Susztak K, Halper-Stromberg E, Tin A, Cristiano S, Chakravarti A, Boerwinkle E, Fox CS, Coresh J, Linda Kao WH (2014) Copy number polymorphisms near SLC2A9 are associated with serum uric acid concentrations. BMC Genet 15:81CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Scott A, Lian Ø, Bahr R, Hart DA, Duronio V, Khan KM (2008) Increased mast cell numbers in human patellar tendinosis: correlation with symptom duration and vascular hyperplasia. Br J Sports Med 42(9):753–757CrossRefPubMedGoogle Scholar
  54. 54.
    Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R (2006) Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 177(9):6370–6378CrossRefPubMedGoogle Scholar
  55. 55.
    Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521CrossRefPubMedGoogle Scholar
  56. 56.
    Shields GE, Beard SM (2015) A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics 33(10):1029–1047CrossRefPubMedGoogle Scholar
  57. 57.
    Thampatty BP, Li H, Im HJ, Wang JH (2007) EP4 receptor regulates collagen type-I, MMP-1, and MMP-3 gene expression in human tendon fibroblasts in response to IL-1 beta treatment. Gene 386(1–2):154–161CrossRefPubMedGoogle Scholar
  58. 58.
    Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini KM (2015) Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther 97(5):518–525CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Yuan J, Murrell GA, Wei AQ, Wang MX (2002) Apoptosis in rotator cuff tendonopathy. J Orthop Res 20(6):1372–1379CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Regenerative Medicine Laboratory, BioCruces Health Research InstituteCruces University HospitalBarakaldoSpain
  2. 2.Department of Medicine and Science of AgingUniversity G. d’AnnunzioChieti Scalo (CH)Italy

Personalised recommendations